Last updated: May 25, 2026
Mometasone furoate supply chains split into (1) API manufacturers and (2) finished-goods and component suppliers for topical and inhaled products. The supplier map depends on dosage form (cream/ointment/lotion, nasal spray, inhalation, and compounded suspensions) and the regulatory listing status in FDA Drug Approval (Orange Book for small molecules).
What suppliers provide the active pharmaceutical ingredient (API) for mometasone furoate?
Mometasone furoate is a generic corticosteroid API used in multiple products and jurisdictions. In practice, “suppliers” typically include:
- API manufacturers (mometasone furoate substance, GMP)
- Contract manufacturers (blend, micronization if needed, fill-finish)
- Component suppliers (excipients, preservatives, solvents, propellants, and device components)
API supply: typical upstream categories
API procurement is usually structured as:
- Mometasone furoate substance under GMP for topical, nasal, and inhalation products
- Intermediates and finishing services (crystallization/purification) when embedded in the API batch record
- Secondary sourcing via DMFs (Drug Master Files) and validated sourcing controls at finished-goods plants
How to identify the API supplier list in a defensible way
A defensible supplier list is built from:
- DMF holder listings for mometasone furoate (API substance) in the US and comparable filings elsewhere
- Finished-goods manufacturer AND strength/dosage form matching (because the same API may come from multiple sources across product lines)
- FDA manufacturing site listings for approved products (establishments and label claims)
The supplier universe changes materially by dosage form and geography because manufacturing sites and qualification status are product-specific.
Which companies supply finished mometasone furoate products (topical creams/ointments/lotions)?
For topical mometasone furoate, “finished supplier” usually means:
- Market authorization holder or branded manufacturer
- Generic/OTC manufacturers supplying the US market through ANDA or OTC drug registrations
- Contract manufacturers producing finished product under label-owner control
Common topical product formats in commerce
- Cream
- Ointment
- Lotion
- Gel/other semi-solids (depending on market and strength)
What matters commercially when picking a topical finished supplier
- Regional approval status for each strength and base type (cream vs ointment changes excipient system)
- Preservative system and device requirements (less variable for semi-solids than for nasal sprays)
- Bioavailability is not the driver; stability, preservative efficacy testing, and physical uniformity are
Who supplies mometasone furoate nasal sprays and what components drive sourcing?
Nasal spray supply has more moving parts than topical semi-solids:
- Actuation device and valve supplier
- Propellant or non-propellant system components (depends on product design)
- Pump performance requirements that must match suspension viscosity and particle size
Nasal spray sourcing categories
- Finished-goods manufacturer
- Spray device supplier (pump/valve, actuator, and dip tube where applicable)
- Excipients for suspension stabilization (buffering agents, suspending agents, viscosity modifiers)
Which firms supply inhaled mometasone furoate products?
Inhaled mometasone furoate is typically tied to:
- Inhalation device platform supply (metered-dose inhaler systems or dry powder systems depending on the product)
- Fill-finish and canister or dose unit sourcing
- Particle engineering and aerosol performance controls (if suspension or blend-based)
Device-driven procurement
For inhaled products, the device supplier can be a gating factor:
- Compatibility of formulation with delivery system
- Metered dose consistency and plume characteristics
- E&L or extractables/leachables validation
How many supplier options exist for mometasone furoate across the major dosage forms?
Supplier count is not fixed; it depends on:
- Strength and dosage form (for example, 0.1% cream vs 50 mcg nasal spray vs inhalation)
- Whether the supplier is an API-only DMF holder, a finished-goods ANDA sponsor, or a contract manufacturer
- Whether the supply chain is US-centric (Orange Book listings) or global
A practical approach to mapping “how many suppliers” is to:
- Enumerate FDA-approved product labels using mometasone furoate (by dosage form and strength)
- Pull each product’s applicant and manufacturing site references
- Map manufacturing sites to corporate entities and then back to API sourcing using DMF links where available
What patents or exclusivity change supplier availability for mometasone furoate?
Mometasone furoate is widely generified, so access is typically less constrained by exclusivity and more constrained by:
- Quality system qualification
- Device component qualification (for nasal/inhaled)
- Stability and regulatory comparability requirements for generics
Supplier selection risk is more often about:
- Raw material change control acceptance (particle size distribution, polymorph form, assay and impurity profile)
- Batch release and ongoing process validation at the chosen CMOs
- Regulatory history for each dosage form
What generic entry risks exist for mometasone furoate suppliers?
For suppliers, generic entry risk typically shows up as:
- Product withdrawal or labeling revisions tied to stability or container-closure issues
- Recalls or warning letters at manufacturing sites
- Device component shortages or lead time volatility for nasal/inhalation formats
Where a generic relies on a particular particle size distribution, sourcing variability in API or milling can drive stability failures and cause batch rejects.
Which regulatory lists should be used to verify mometasone furoate suppliers in the US?
In the US, the two most actionable lists for supplier mapping are:
- Orange Book for approved applications tied to specific dosage forms and strengths (helps link product applicants to manufacturing networks)
- FDA establishment and inspection records linked to the marketed product label
For APIs specifically:
- DMF listings (when available for the relevant substance) are the usual route to identify API holders
Key supplier decision checklist for mometasone furoate sourcing
- Dosage form match: API lot acceptance criteria differ by semi-solid vs suspension vs inhalation blend
- Impurity profile alignment: ensure supplier spec mirrors the approved reference product’s acceptance where applicable
- Device and container closure compatibility: especially for nasal sprays and inhalers
- Stability program: match temperature excursion and photostability protocols
- Quality agreements: audit frequency, change control, and notification timelines for source changes
Key Takeaways
- Mometasone furoate supply is best mapped by dosage form: topical, nasal spray, and inhaled products rely on different component and manufacturing qualification networks.
- “Suppliers” should be split into API suppliers (mometasone furoate substance), component suppliers (device and excipients), and finished-goods manufacturers.
- Generic supplier availability depends less on patents (widely generified) and more on quality-system qualification, stability performance, and device compatibility.
FAQs
1) Which excipients most affect stability for mometasone furoate topical creams and ointments?
Suspending agents, preservatives, buffering systems, and emollient bases drive uniformity and phase stability; cream vs ointment bases materially change formulation behavior.
2) How does particle size of mometasone furoate affect nasal spray performance?
Particle size distribution influences suspension sedimentation rate, sprayability, and plume quality, which can affect both efficacy proxy and stability.
3) What documentation is typically required from mometasone furoate API suppliers for commercial batches?
GMP batch records, CoA with impurity profile, identity and assay methods, residual solvent where applicable, and change-of-source documentation under agreed quality agreements.
4) What are the biggest supply bottlenecks for mometasone furoate nasal sprays?
Spray pump/valve components and container-closure systems, followed by suspension-related stability constraints at the finished-goods manufacturer.
5) Do mometasone furoate generics face different manufacturing site constraints than the reference product?
They can. Regulatory acceptance is tied to validated manufacturing controls, stability, and comparability, so the manufacturing site network is often a gating factor.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
- FDA. Drug Master Files (DMF) and related regulatory guidance. (Accessed via FDA DMF information pages).
- FDA. Drug Establishments Current Registration Site. (Accessed via FDA establishment listings).
